Vascular and Metabolic Effects of Fenofibrate/Omega vs Fenofibrate
Information source: Gachon University Gil Medical Center
ClinicalTrials.gov processed this data on August 23, 2015 Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Hypertriglyceridemia
Intervention: placebo (Drug); fenofibrate/omega (Drug); fenofibrate (Drug)
Phase: Phase 4
Status: Completed
Sponsored by: Gachon University Gil Medical Center
Summary
The investigators hypothesize that fenofibrate/omega will improve insulin resistance
compared with fenofibrate
Clinical Details
Study design: Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment
Primary outcome: flow-mediated dilation
Secondary outcome: insulin resistance
Eligibility
Minimum age: 25 Years.
Maximum age: 80 Years.
Gender(s): Both.
Criteria:
Inclusion Criteria:
- hypertriglyceridemia
Exclusion Criteria:
- moderate or severe hypertension, uncontrolled diabetes (HbA1c > 9%), nephrotic
syndrome, hypothyroidism, coronary artery disease, or peripheral vascular disease
Locations and Contacts
Gil Medical Center, Incheon 405-760, Korea, Republic of
Additional Information
Starting date: January 2012
Last updated: November 1, 2014
|